Key Highlights

  • CurveBeam AI Ltd (ASX:CVB) shares closed at $0.021 on 21 October 2026, up 16.67%.
  • Five HiRise purchase orders were secured in Q1 FY27, and HiRise received regulatory clearance in China on 12 October 2026.
  • Customer receipts were A$1.80 million and the quarter closed with cash of A$5.83 million.

CurveBeam AI Limited (ASX:CVB) shares rose 16.67% to close at $0.021 during the trading session on 21 October 2026, while the S&P/ASX 200 (XJO) stood at 8,809.20, down 7.70 points or 0.087%. The company develops point-of-care specialised medical imaging (CT) equipment and AI-enabled, SaaS-based clinical assessment solutions.

What CurveBeam AI does

CurveBeam AI, headquartered in Melbourne with global operations in Hatfield, Pennsylvania, develops point-of-care CT imaging equipment and AI-enabled software for clinical assessment. Its HiRise system is a weight-bearing CT device, and the company is also developing CT-based bone mineral density (BMD) technology.

The company works with strategic partner Weiying and WEGO Orthopaedics in China, and with robotic-assisted orthopaedic surgery platforms as part of its validation work.

Quarterly activity report: orders and receipts

On 21 October 2026, CurveBeam AI released its Appendix 4C and quarterly activity report for the period ended 30 September 2026 (Q1 FY27). Amid today’s share price gain, this update gains attention. Purchase orders for five HiRise devices were received, two in the United States and three in Europe, which the company described as its best Q1 sales result to date.

Customer receipts were A$1.80 million, down 30% from A$2.58 million in Q4 FY26 but up 31% from A$1.37 million in the comparable quarter of FY26. The company carried A$4.2 million of purchase orders and receivables into Q1 FY27 and carries A$4.9 million into Q2 FY27. It noted that revenue recognition typically takes two to six months from purchase order to installation and full payment.

China clearance and milestone payments

Following responses to the National Medical Products Administration’s (NMPA) second round of feedback, HiRise received regulatory clearance in China on 12 October 2026. The milestone triggers a A$1.0 million payment from Weiying and is expected to pave the way for an initial order of US-manufactured HiRise systems from Weiying/WEGO for distribution in China.

A further A$3.0 million in milestone payments is payable in relation to HiRise sales in China: A$1.0 million on sale of the first 10 systems and A$2.0 million on sale of the first 50 systems, in addition to product sales revenue. WEGO purchase orders are payable 50% on order, 20% on shipment and 30% when installed. Launch preparation activities in the quarter included key opinion leader outreach, identification of prospective reference sites and training on manufacturing, assembly and service.

FDA clearance, robotic surgery work and cost reductions

During September, the company received US Food and Drug Administration 510(k) clearance for its first CT-based BMD product for multidetector CT scans. The company plans to complete validation of automated region-of-interest selection and T and Z score reporting, and to use the clearance as a foundation for a second, Special 510(k) submission to expand the capability onto the HiRise platform.

In robotic-assisted surgery, the company reported that trial scans showed HiRise data could be processed through applicable software workflows, with motion failure rates below acceptable thresholds, in formal validation for total knee replacement. Validation has been expanded to include total hip replacement.

The company also reduced operating expenses during the quarter, including staff reductions, lowering annualised cash-related operating expenditure to approximately A$15 million.

Capital raising and cash position

CurveBeam AI raised a total of A$7.35 million through a A$5.0 million placement at A$0.02 per share, a share purchase plan raising A$0.6 million at A$0.018 per share, and a shortfall offer and further placement raising A$1.75 million at A$0.018 per share. Cash used in operations in Q1 FY27 was A$1.36 million compared with A$2.42 million in Q4 FY26, and the quarter closed with a cash balance of A$5.83 million, equal to about 4.3 quarters of cash based on operating cash outflows.

Sector context

Orthopaedic imaging and robotic-assisted surgery are areas in which hospitals and clinics evaluate equipment through trials, regulatory clearances and integration with existing software workflows. Medical device sales cycles can be lengthy, which is consistent with the two-to-six-month timing the company gives between purchase order and installation. Regulatory clearance in each jurisdiction, such as the FDA and NMPA, is generally required before commercial distribution.

Risks and uncertainties

Customer receipts fell compared with the prior quarter, and the timing of receipts depends on installations. Milestone payments in China depend on future system sales, and the report does not guarantee sales volumes. The company is still reducing costs and has relied on equity capital raisings priced at A$0.018 to A$0.02 per share. Regulatory submissions, validation work with robotic-surgery platforms and the China launch are subject to timing and outcome uncertainty.

What’s next

Items flagged include the initial Weiying/WEGO order of US-manufactured HiRise systems for China, completion of BMD validation work, the planned Special 510(k) submission, continued validation of HiRise datasets for total knee and hip replacement, and the A$4.9 million of purchase orders carried into Q2 FY27.